MindWalk (NASDAQ:HYFT) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of MindWalk (NASDAQ:HYFT) from a strong sell rating to a hold rating in a research report report published on Monday,Zacks.com reports.

Separately, Weiss Ratings started coverage on MindWalk in a research note on Wednesday, January 14th. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

MindWalk Stock Down 0.7%

Shares of MindWalk stock opened at $1.38 on Monday. The stock has a market capitalization of $63.70 million, a P/E ratio of -2.30 and a beta of 0.51. MindWalk has a one year low of $0.27 and a one year high of $3.25. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.19 and a quick ratio of 4.09.

Institutional Trading of MindWalk

Several institutional investors and hedge funds have recently bought and sold shares of HYFT. Jane Street Group LLC boosted its stake in MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after acquiring an additional 96,018 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of MindWalk during the fourth quarter valued at $91,000. Bank of Montreal Can raised its position in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after purchasing an additional 18,600 shares in the last quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.